Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) single-dose vial.

About the Product:

• Indication: Used to raise blood pressure in adult patients with acute hypotension (low blood pressure).
• Category: A critical care medication commonly used in hospital settings.

Significance of the Approval:

This approval strengthens Biocon Pharma’s portfolio of complex drug products and reinforces its commitment to providing high-quality, affordable generics to the U.S. market.

Search keyword: Biocon Pharma Share Price, Biocon Pharma Stock Analysis, Biocon Pharma Latest News, Biocon Pharma Quarterly Results, Biocon Pharma Future Outlook, Biocon Pharma Investment Opportunity, Biocon Pharma Stock Forecast, Biocon Pharma Financial Performance, Biocon Pharma Share Market Update, Biocon Pharma Fundamental Analysis, Biocon Pharma Technical Analysis, Biocon Pharma Growth Potential, Biocon Pharma Dividend Updates, Biocon Pharma Breaking News,